LBBAP implant
DeviceUse of Smart ECG system during the LBB implant
NCT Number: NCT07254013
To evaluate the capability to monitor LBB success criteria with the use of a Smart ECG system (ECG monitor, 12 leads ECG cable, ECG viewer software ) during a cardiac device implantation involving the placement of a pacing lead in interventricular septum area
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
CHU de Besançon, Besançon, France
The clinical investigation aims to support physicians with a portable and easy to use solution to display ECG and to provide automatic calculation of key ECG indicators (Left Ventricular Activation time (LVAT) and V6-V1 interval) for LBB implantation procedure. This allows physicians to concentrate on lead placement with the benefice from immediate ECG measurements thanks to the automatic software.
The Smart ECG system is class IIA device and it is composed of:
The study is a pre-market, non-pivotal study: HookUp Smart V2 software is a non-implantable Class IIA device, with no interaction with the human body and the demonstration of conformity with general safety and performance requirements is based on the results of non-clinical testing methods alone (as article 61(10) from MDR.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use of Smart ECG system during the LBB implant
Time frame: baseline/ procedure
Proportion of investigators providing an overall favorable assessment (assessed "GOOD or ACCEPTABLE") on a four- point scale (GOOD, ACCEPTABLE, POOR, VERY POOR) on the use of Smart ECG system to achieve LBB area pacing.
Time frame: baseline/ procedure
The accuracy of the two measurements (LVAT and V6-V1) during the final LBB lead position (LBBAP) will be assessed separately by comparing manual and automatic methods.
Time frame: baseline/ procedure
Concordance between EP and Smart ECG for the identification of LBB transitions (non-selective to selective or non-selective to LVSP, during threshold test at final lead position)
Time frame: baseline/ procedure
Concordance of type of LBB capture as determined by EP vs Smart ECG signals (LBBAP, likely LBBAP, LVSP) - based on centralized blinded review of EP annotated screenshot and Smart ECG recordings
Time frame: baseline/ procedure
Comparison of Smart ECG versus EP signal quality analysis (signal to noise ratio, frequency analyses)
Time frame: baseline/ procedure
Investigator's satisfaction questionnaire about using Smart ECG system during the full procedure (i.e .setting the system for the procedure, monitoring lead progression, assessing pacing capture)
Time frame: baseline/ procedure
To report any SADE, ADE, DD occurred during the investigational procedure
Contact information is provided by the study sponsor or research team.
MicroPort CRM
Industry
Acronym: LBBOT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05815745
Arrhythmias, Cardiac, Bradycardia
Dublin, Ireland
View Trial DetailsNCT07217392
Arrhythmias, Cardiac, Atrial Fibrillation
Rio de Janeiro, Brazil
View Trial DetailsNCT06453850
Arrhythmias, Cardiac, Bradycardia
Coimbra, Portugal
View Trial DetailsNCT07342608
Arrhythmias, Cardiac, Bradycardia
View Trial Details